Responses

Download PDFPDF
The use of placebo in a trial of rectal artesunate as initial treatment for severe malaria patients en route to referral clinics: ethical issues
Compose Response

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Statement of Competing Interests

PLEASE NOTE:

  • Responses are moderated before posting and publication is at the absolute discretion of BMJ, however they are not peer-reviewed
  • Once published, you will not have the right to remove or edit your response. Removal or editing of responses is at BMJ's absolute discretion
  • If patients could recognise themselves, or anyone else could recognise a patient from your description, please obtain the patient's written consent to publication and send them to the editorial office before submitting your response [Patient consent forms]
  • By submitting this response you are agreeing to our full [Response terms and requirements]

Vertical Tabs

Other responses

  • Published on:
    Lack of alternative to rectal artesunate for pre-referral treatment of malaria ? Rectal quinine as an available and effective health tool
    • Hubert Barennes, Training and research coordinator
    • Other Contributors:
      • Eric Pussard

    In developing countries, most cases of malaria occur in rural areas far from hospitals, where health care providers cannot adequately manage severe malaria cases. Hospital referral causes treatment delays. Most deaths occur during the first 24 hours, highlighting the need for earlier actions to reduce mortality. Gomes and colleagues reported recently the benefits of pre-referral rectal artesunate.(1) A single pre-referra...

    Show More
    Conflict of Interest:
    None declared.